Table 6 Results of phase II trials in esophageal cancer

Lee [20]

XP (X:2,500 mg/m² D1-14

CDDP:60 mg/m²; D1)

SCC

(n = 45)

1^st line

(n = 45)

57.8%

4.7 mon

11.2 mon

Van Meerten [18]

XELOX

(X:2,000 mg/m² D1-14

O:130 mg/m²; D1)

ADC (n = 45)

SCC (n = 4)

Undiff. (n = 2)

1^st line

(n = 51)

39%

NR

8 mon

MB Polee [28]

Paclitaxel:180 mg/m²;D1

CDDP:60 mg/m²; D1

ADC (n = 31)

SCC (n = 16)

Undiff (n = 4)

1^st line

(n = 51)

ADC (39%)

SCC (44%)

NR

9 mon

Zhang [29]

Paclitaxel:175 mg/m² on D1

CDDP:75 mg/m² (D1)

SCC

(n = 35)

1^st line

(n = 35)

48.6%

7 mon

13 mon

S.Lorenzen [21]

DX

(X:2,000 mg/m² D1-14

D:75 mg/m²; D1)

ADC (n = 7)

SCC (n = 17)

1^st (n = 16)

2^nd (n = 8)

1^st (56%)

2^nd (25%)

Overall = 46%

6.1 mon

1^st (15.8)

2^nd (6.2)

S.Lorenzen [26]

FP + Cetuximab vs

FP

SCC (n = 62)

1^st line

(n = 62)

FP+ Cetuximab (19%)

FP (13%)

5.9 mon

3.6 mon

9.5 mon

5.5 mon

Current Study

Xeloda 1,800 mg/m² D1-14

Paclitaxel:80 mg/m² on D1, D8

SCC (n = 32)

1^st (n = 12)

2^nd (n = 20)

1^st (75%)

2^nd (45%)

Overall = 53.6%

5.23 mon

4.54 mon

14.3 mon

8.4 mon